Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 1;43(5):e155-e159.
doi: 10.1097/INF.0000000000004271. Epub 2024 Feb 2.

Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe

Farihah Malik  1 , Siobhan Crichton  2 , Yulia Plotnikova  3 , Inga Latysheva  4 , Anna Samarina  5 , Maria Pokorska-Śpiewak  6 , Marisa Navarro Gomez  7 , Heather Bailey  8 , Claire Thorne  1 , Ali Judd  2 , Anna Turkova  2 , Intira Jeannie Collins  2
Collaborators, Affiliations

Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe

Farihah Malik et al. Pediatr Infect Dis J. .

Abstract

We evaluated the effectiveness and safety of direct-acting antivirals in adolescents with hepatitis C (HCV)/HIV coinfection using pooled individual patient-level data from 5 European cohorts. Of 122 participants in follow-up from November 2013 to August 2021, 19 were treated <18 years of age; of 15 with HCV RNA available at/after 12 weeks post-treatment, all had sustained virologic response with acceptable safety. This evidence addresses an important gap in knowledge of treatment outcomes in adolescents with HCV/HIV coinfection in real-life settings.

PubMed Disclaimer

Conflict of interest statement

C.T. has previously received grant funding from ViiV Healthcare (through Penta Foundation). I.J.C. and A.J. report grants from Gilead, ViiV Healthcare and AbbVie (including through the Penta Foundation). A.J. is a member of the TiP-HepC Registry Scientific Advisory Committee, and also the HIV, Hepatitis and STIs Pregnancy and Breastfeeding Therapeutics Working Group (HHS PTWG), World Health Organization. A.T. is a member of Paediatric Working Group on Viral Hepatitis and Paediatric Antiretroviral Working Group, World Health Organization and a member of WHO Guidelines Development Group on Clinical Recommendations for the Prevention of HIV and the Treatment and Care of People Living with HIV. The other authors have no conflicts of interest to disclose.

Figures

FIGURE 1.
FIGURE 1.
Participant selection from eligible cohorts in EPPICC. *First IFN-free regimen approved by EMA for adult use November 22, 2013. **Transferred to another center or to adult care. †Treated at age ≥18 years. DAA indicates direct-acting antiviral; IFN, interferon; LTFU, lost to follow-up.
See this image and copyright information in PMC

References

    1. Indolfi G, Bartolini E, Serranti D, et al. . Hepatitis C in children co-infected with human immunodeficiency virus. J Pediatr Gastroenterol Nutr. 2015;61:393–399. - PubMed
    1. Indolfi G, Easterbrook P, Dusheiko G, et al. . Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:477–487. Available at: http://www.ncbi.nlm.nih.gov/pubmed/30982721. Accessed July 2, 2019. - PubMed
    1. European Paediatric HIV/HCV Co-infection Study Group E. Coinfection with HIV and hepatitis C virus in 229 children and young adults living in Europe. AIDS. 2017;31:127–135. Available at: https://pubmed.ncbi.nlm.nih.gov/27898593/. Accessed July 5, 2021. - PubMed
    1. Zoratti MJ, Siddiqua A, Morassut RE, et al. . Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta-analysis. EClinicalMedicine. 2020;18:100237. Available at: http://www.thelancet.com/article/S2589537019302421/fulltext. Accessed December 3, 2021. - PMC - PubMed
    1. WHO. Updated Recommendations on Treatment of Adolescents and Children With Chronic HCV Infection: Policy Brief. Geneva: 2022. - PubMed

Substances